Trading Statement

Alliance Pharma PLC
10 January 2006


For immediate release                                            10 January 2006

                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                            PRE-CLOSE TRADING UPDATE

Alliance Pharma plc, the emerging speciality pharmaceutical company, which last
year announced a change to its year-end from 28 February to 31 December, is
pleased to report on trading for the year ending 31 December 2005.

As guidance on the annualised growth rate, sales for the 12 months ending 31
December 2005 were 25% greater than for the previous 12 month period.

Sales for the ten month period ending 31 December 2005 are expected to be in the
region of £12.2 million, up from £11.8 million for the 12 months ending February
2005. Profits are anticipated to be within the range of analysts' expectations.

John Dawson, Alliance Pharma's Chief Executive, commented: 'We are very pleased
with the Company's trading during the period. We have successfully integrated
our two acquisitions made in November 2004, namely Periostat, for periodontitis,
and Forceval, our prescription nutritional supplement. We have also maintained
growth in our dermatology range, in our Parkinson's disease product Symmetrel
and in Nu-Seals, our low dose, coated aspirin for cardiovascular protection.'

Preliminary results for the 10 month period to 31 December 2005 will be
announced on 23 March 2006.

                                    - ends -

For further information:

Alliance Pharma plc                                        + 44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                   + 44 (0) 20 7466 5000

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 30 branded pharmaceutical products and continues
to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.

Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.



                      This information is provided by RNS
            The company news service from the London Stock Exchange